Analysts Set Insmed Incorporated (NASDAQ:INSM) PT at $82.73

Insmed Incorporated (NASDAQ:INSM) has been assigned an average recommendation of “Buy” from the sixteen brokerages that are presently covering the stock, Marketbeat.com reports. Sixteen research analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have issued a report on the stock in the last year is $82.73.

Several equities research analysts recently commented on INSM shares. TD Cowen boosted their price objective on shares of Insmed from $75.00 to $98.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. UBS Group boosted their price objective on shares of Insmed from $78.00 to $84.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. StockNews.com downgraded shares of Insmed from a “hold” rating to a “sell” rating in a research note on Friday, August 9th. Bank of America upped their target price on shares of Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Finally, Stifel Nicolaus upped their target price on shares of Insmed from $74.00 to $88.00 and gave the stock a “buy” rating in a research note on Friday, August 9th.

Insider Activity

In other Insmed news, insider Michael Alexander Smith sold 27,871 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $74.35, for a total transaction of $2,072,208.85. Following the completion of the sale, the insider now directly owns 67,856 shares of the company’s stock, valued at approximately $5,045,093.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Insmed news, insider Michael Alexander Smith sold 27,871 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $74.35, for a total transaction of $2,072,208.85. Following the completion of the sale, the insider now directly owns 67,856 shares of the company’s stock, valued at approximately $5,045,093.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Martina M.D. Flammer sold 13,436 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the sale, the insider now directly owns 106,134 shares of the company’s stock, valued at approximately $7,951,559.28. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 78,882 shares of company stock valued at $5,765,446 over the last three months. Insiders own 4.60% of the company’s stock.

Institutional Trading of Insmed

A number of hedge funds and other institutional investors have recently modified their holdings of INSM. American International Group Inc. boosted its position in shares of Insmed by 4.4% during the fourth quarter. American International Group Inc. now owns 68,710 shares of the biopharmaceutical company’s stock worth $2,129,000 after acquiring an additional 2,921 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in shares of Insmed by 6.4% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 146,912 shares of the biopharmaceutical company’s stock worth $3,986,000 after acquiring an additional 8,877 shares during the last quarter. Diversified Trust Co boosted its position in shares of Insmed by 5.2% during the first quarter. Diversified Trust Co now owns 21,684 shares of the biopharmaceutical company’s stock worth $588,000 after acquiring an additional 1,078 shares during the last quarter. Requisite Capital Management LLC bought a new position in Insmed during the first quarter valued at $678,000. Finally, Fidelis Capital Partners LLC bought a new position in Insmed during the first quarter valued at $34,000.

Insmed Stock Performance

Shares of INSM opened at $70.96 on Thursday. The company has a debt-to-equity ratio of 25.05, a current ratio of 2.71 and a quick ratio of 2.53. Insmed has a one year low of $21.92 and a one year high of $80.53. The company has a 50-day simple moving average of $73.83 and a two-hundred day simple moving average of $60.03. The firm has a market capitalization of $12.19 billion, a PE ratio of -13.17 and a beta of 1.11.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The business had revenue of $90.34 million for the quarter, compared to analyst estimates of $87.95 million. During the same period in the previous year, the business earned ($1.78) EPS. Insmed’s revenue for the quarter was up 17.0% compared to the same quarter last year. On average, analysts anticipate that Insmed will post -5.41 EPS for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.